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Abstract
Objective: The role of biochemical and functional markers of microvascular dysfunction to
predict cardiovascular (CV) outcomes in non-dialyzed chronic kidney disease (CKD) remains
unclear. In this prospective cohort study we assessed whether biochemical (serum level of
angiopoietin-2 (Ang-2), asymmetric and symmetric dimethylarginin (ADMA, SDMA)) and
functional (laser Doppler flowmetry (LDF)) measures of microvascular function predicted CV
events, CV and all-cause mortality in CKD patients.
Methods: Post-occlusive reactive hyperemia area (PORHHA), acetylcholine and sodium
nitroprusside-mediated flow changes were estimated by LDF and Ang-2, ADMA and SDMA
were assessed in 105 CKD patients at baseline. Multiple failure time Cox-regression analyses
with backward elimination were performed to determine the predictors of the combined
endpoint of CV mortality plus CV events or all-cause mortality plus CV events during a
median of 66.6 (IQR 39.8-80.4) months of follow-up.
Results: In univariate models lnAng-2 and lnPORHHA both predicted the CV outcome
besides age, diabetes, baseline CV disease, brachial pulse pressure and lnCRP. In multivariate
analysis lnPORHHA (HR: 0.66 (95%CI: 0.49-0.89) per ln(mU*sec)), age (1.03 (1.01-1.06) per
year), lnCRP (1.31 (1.06-1.64) per ln(mg/L)) and diabetes (3.33 (1.70-6.53)) remained
significant predictors of the CV outcome while lnAng-2 did not enter the model. Neither of
the microvascular variables were an independent predictor of all-cause mortality plus CV
events.
Conclusions: Among the functional and biochemical microvascular parameters PORHHA
seems to improve CV risk assessment in CKD. Nevertheless the robustness of traditional risk
factors seems to outweigh the role of microvascular biomarkers on all-cause mortality plus
CV events at this time.
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Introduction
Cardiovascular (CV) disease is the major cause of morbidity and mortality in patients
with chronic kidney disease (CKD)[1]. Furthermore, CV mortality in CKD patients is even
more frequent than progression of renal failure to end-stage renal disease (ESRD)[2]. The
development of CV disease in CKD patients involves the complex processes of progressive
athero- and arteriosclerosis that includes microvascular dysfunction[3].
Following the discovery of the pivotal role of nitric oxide (NO) in endothelium-derived
vascular relaxation by Furchgott and Zawadzki in 1980[4], different methods have been
developed and used in laboratories for the early diagnosis of subclinical atherosclerosis and
microvascular dysfunction. Only a few of these, however, such as the detection of minute
amounts of albuminuria, increased high-sensitivity C-reactive protein levels or the
measurement of carotid intima-media thickness have gained role in everyday practice[5].
Laser Doppler flowmetry (LDF) allows the non-invasive assessment of skin microvascular
reactivity. Different tests have been developed for the evaluation of microcirculation with
LDF. Using LDF with iontophoresis of acetylcholine and sodium nitroprusside or with the
post-occlusive reactive hyperemia test (PORH) of the capillaries of the forearm we previously
demonstrated endothelial dysfunction in patients with hypertension[6] and patients on
dialysis[7].
Endothelial dysfunction could be estimated by different serum molecules that could also
be linked to CV events in CKD, such as angiopoietin-2 (Ang-2), asymmetric dimethylarginin
3(ADMA) or symmetric dimethylarginin (SDMA)[8-10]. Ang-2 functions as a dynamic
autocrine negative regulator of the quiescent endothelium through inhibiting the endothelial
receptor tyrosine kinase Tie-2-regulated signal transduction pathways[11]. Previously we
found that Ang-2 increases with advanced CKD[12] and in a combined cohort of CKD
patients stage 4 and 5, it was a predictor of mortality [8]. However, its predictive value for CV
outcome on non-dialyzed CKD patients has never been tested.
ADMA and its isomer SDMA are endogenous products of methylated protein turnover
that are present in the circulation in micromolar levels[13]. ADMA directly inhibits nitrogen-
monoxide (NO) synthesis by competitively binding nitrogen-monoxide synthases (NOS), and
both ADMA and SDMA may also reduce NO production by inhibiting the cellular uptake of
L-arginine, a precursor of NO[13]. Both of these molecules are potential biomarkers of CV
outcome in CKD, but their importance has not been conclusively clarified yet.
When a biological measure applies to be a marker of cardiovascular risk, among others,
follow-up studies are also required to demonstrate its predictive value for different outcomes
before their introduction into clinical practice [14]. While many groups used LDF to evaluate
endothelial dysfunction, only one work is available in ESRD patients about its predictive
value for cardiovascular mortality[15] and none in non-dialyzed CKD. Furthermore, neither
the correlation, nor the predictive superiority of biomarkers vs. LDF to depict endothelial
dysfunction and CV events has been shown in non-dialyzed CKD patients.
Therefore the aim of our study was to evaluate whether traditional risk factors, LDF
parameters of iontophoresis and PORH were related to markers of microvascular dysfunction,
such as Ang-2, ADMA and SDMA in stage 1-5 CKD non-dialyzed patients. We also aimed to
study the prognostic importance of these parameters in our patients for CV events and CV or
all-cause mortality. We hypothesized, that the functional and biochemical markers of
4microvascular dysfunction would be associated with each other and that they would be
predictors of CV events.
Materials and Methods
This was a prospective cohort study of hypertensive CKD patients with baseline cross-
sectional analysis between the LDF parameters and biochemical markers of microvascular
function, and analysis of these microvascular markers as predictors for CV events, CV- and
all-cause mortality during follow-up. Initially 108 patients were enrolled but finally only 105
patients were followed-up and analyzed as three patients could not be contacted after the
initial measurements.
Convenience sampling was used with consecutive inclusion of CKD patients presenting
at two tertiary care nephrology outpatient clinics who were invited to participate in the study.
None of the patients were hospitalized at the time of baseline investigations. No other specific
exclusion criteria were applied. Antihypertensive treatment was tailored according to the
latest recommendations of the European Society of Hypertension[16]. CKD patients in stage
1-5, non-dialyzed, who gave written informed consent for participation, were included and
two appointments within the next two weeks for blood sampling and LDF measurements was
arranged, Then patients were followed for a median of 66.6 months (interquartile range: 39.8-
80.4). Follow-up data were collected between April 2007 and July 2014 by telephone
interviews with the patients, their general practitioners or treating physicians, and the
information gathered were in all cases verified by chart review. Follow-up was censored at the
last occurrence of a documented CV event (acute coronary syndrome, heart failure requiring
hospitalization, stroke or transient ischemic attack, peripheral artery disease verified by
angiography or need for an intervention) or death due to the above CV events or any other
causes. Laboratory data and vascular biomarkers were not collected during follow-up.
5The protocol was approved by the Ethics Committees of the two hospitals that the outpatient
clinics belonged to and was carried out in accordance with the tenets of the Declaration of
Helsinki.
Epidemiologic and laboratory data
Baseline data on smoking habits (current), diabetes (DM, any type), hypertension,
coronary artery disease (previous acute myocardial infarction or coronary intervention),
chronic heart failure (previous diagnosis), peripheral artery disease (documented by
angiography or intervention) and cerebrovascular disease (previous stroke or transient
ischemic attack) were collected by health record review. Framingham 10-year cardiovascular
risk scores were calculated for sensitivity analysis of the results[17].
Blood samples were taken after overnight fasting, between 7.00-8.00 a.m. On that
morning regular medications were not taken, but there has been no medication withdrawal on
previous days. Serum levels of hemoglobin, potassium, calcium, phosphorus, albumin,
creatinine, C-reactive protein (CRP), cholesterol, were evaluated at baseline by a Hitachi
auto-analyser. Intact parathormone 1-84 was determined by an immune-chemiluminometric
two-site assay (CIBA-CORNING, Frenwald, Germany). Baseline eGFR was calculated using
the four-variable Chronic Kidney Disease Epidemiology Collaboration equation. Albuminuria
was characterised by albumin-to-creatinine ratio measured from first morning spot urine
sample. Circulating serum Ang-2 concentrations were measured by an in-house
immunoluminometric assay (ILMA) as previously reported by our group in details[18]. The
coefficient of variation was <6%. The sensitivity threshold was 0.2 ng/ml. Assays were
performed in duplicate by a single investigator blinded to patients' characteristics and
outcome. Plasma ADMA and SDMA levels were assessed using high-performance liquid
chromatography-tandem mass spectrometry[19].
6Laser Doppler flowmetry measurements
LDF measurements were performed at the second appointment between 10-12 a.m. Patients
had a non-standardized light breakfast and took their regular medications 3 hours before the
LDF measurements. Patients were asked to refrain from smoking on the day of the study and
not to consume caffeine-containing drinks at least 4 hours before the start of the
measurements. LDF measurements and blood sampling were done on separate days within a
week.
LDF measurements were carried out in a temperature-controlled room (241C). Upon arrival
and a 5-minute rest, two consecutive brachial blood pressure measurements were taken one
minute apart on each arm in the sitting position with a validated BpTru device (VSM
Medtech, Vancouver, Canada). The mean value was calculated for each arm, and the higher
of these was further taken as brachial systolic and diastolic blood pressures and heart rate.
Then subjects were set in the supine position for a 20-minute acclimatization period. Before
starting the LDF measurements, the flexor surface of the right forearm was gently cleansed
using alcohol solution.
The laser Doppler instrument Periflux 5001 (wavelength 780 mm) and the
micropharmacology system PeriIont was used during the study. The same iontophoresis
protocols were used as in our previous studies[6, 7]. The drug delivery electrode was filled
with 140 µl acetylcholine 1% (Clinalfa AG, Switzerland) and was attached with the laser
probe to the volar surface of the right forearm. The position of the probe was chosen in order
to avoid hair, freckles and broken skin. The dispersive electrode was attached to the volar
aspect of the wrist to complete the circuit. We placed a control standard probe 4 cm laterally
from the drug delivery electrode. After registration of the baseline flow (60 s) two doses of
acetylcholine were delivered using an anodal current (0.1mA for 30 s and 0.16mA for 30 s)
7with a 120 s interval. Using a new delivery electrode two doses of sodium nitroprusside 1%
(Nitropress, ABBOTT, USA) were delivered using a catodal current (0.1mA for 20 s and
0.1mA for 30 s) with a 120 s interval.
During the postocclusive reactive hyperemia (PORH) test after the registration of the baseline
flow (60 s) arterial occlusion was performed with a suprasystolic pressure using the
pneumatic cuff of a sphygmomanometer for 3 min (biological zero), then after the release of
the pressure we measured the skin hyperemia on the volar surface of the left forearm 10 cm
below the elbow with a standard laser Doppler probe. Another standard probe was put on the
skin of the right forearm as a control.
About the principles of LDF measurements we also refer to our previous publications[6, 7].
The LDF output is semi-quantitative and is expressed in perfusion units (PU) of output
voltage (1 PU = 10 mV) in accordance with the general consensus (European Laser Doppler
Users Groups, London 1992). Because the output is not easily translated into absolute values
of blood flow, in case of iontophoresis, the magnitude of the change in skin perfusion after the
second administered dose of acetylcholine or sodium nitroprusside was calculated as the ratio
between peak and baseline perfusion and expressed as percent of baseline (ACh, SNP values).
In case of PORH, the software analyzed the data automatically and calculated several indexes
such as the initial baseline value, slope value, peak flow, percent change in perfusion from
baseline to maximum values, time to reach the maximum hyperemia, time to reach the half
value after the maximum hyperemia, and the area of hyperemia. This latter measure
(abbreviated as: PORHHA, unit: PU*sec – perfusion unit * second) seems to be the most
accurate parameter to assess the hyperemic response, as it includes three variables (speed,
intensity, and duration) and this was used in the analyses as representative of the
microvascular function of PORH[20, 21].
8According to previous measurements in our laboratory[6], the day to day variability of
this system was 16-21%, which is comparable to other studies[21] and to the wildly accepted
brachial artery flow-mediated vasodilation technique (17.5%)[22]. The LDF measurements
were performed and analyzed by the same examiners (JN, JE, GG, LS) throughout the study.
Statistical analysis
All data analysis was performed by STATA IC version 10.0 (StataCorp Lp. Texas
USA) and Statistica version 11.0 (StatSoft Inc. Tulsa USA). Continuous data are given as
mean and standard deviation, or in case of evidence against normal distribution, as median
and interquartile range. For further analyses non-normally distributed data were transformed
logarithmically. All those variables that were log-transformed had positively skewed
distribution that improved after the transformation visually although not all satisfied tests for
normality. Thus in the statistical modeling described in the next paragraphs, log-transformed
and non-log transformed variables were included in the models simultaneously. In the group
comparisons of anthropometric and clinical parameters Student’s t-test for independent
samples, Mann Whitney U tests and chi-squared tests were used, as appropriate.
In the baseline cross-sectional analyses first Spearman correlations were run between
the six microvascular parameters (ACh, SNP, PORHHA, Ang-2, ADMA, SDMA). Then,
univariate and multivariate linear regressions were performed to determine associations of
these six microvascular parameters with baseline clinical variables and used medications. The
predictor clinical variables considered were the ones listed in table 1. The variables that
showed a significant association with the given microvascular variable in univariate models
were considered in the final multivariate model.
The primary outcome of the study was the occurrence of the combined endpoint of CV
events and CV mortality or CV events and all-cause mortality, as defined above.
9To assess the predictive values of ACh, SNP, PORHHA, Ang-2, ADMA and SDMA for
the primary outcome multiple failure times Cox proportional hazard regression analyses were
used with conditional risk set modeling. This method accommodates for the fact that one
patient may have had more than one event during follow up. We first performed univariate
analyses considering variables listed in Table 1 and all groups of medications. Confounding
was addressed in multivariate Cox-regression models with adjustment for potential clinical
predictors. In case of medications those groups were considered that were independently
related to the three LDF or three biochemical parameters listed in table 3 or those that showed
a univariate association with the outcomes (p<0.1). In the final multivariate models instead of
the use of separate variables for "oral antidiabetic drugs" and "insulin", the variable "diabetes"
was used, as these two groups did not improve the Cox-models. Final models were selected
using backward elimination to reach the most parsimonious models. As a sensitivity analysis
we repeated these analyses using the other endpoint (CV events plus all-cause mortality) as
the outcome. For further sensitivity analysis area under the receiver-operator characteristics
curves were compared and net reclassification improvement (NRI) was calculated from the
probability scores of logistic regression models using the Framingham cardiovascular risk
score and lnPORHHA as predictors and both primary outcomes as dependent variables[23].
A p-value with a two-sided alpha of <0.05 was considered statistically significant.
Hazard ratios are presented with their corresponding 95% confidence intervals.
Results
We report data on 105 patients with CKD at the two centers who had follow-up data. Baseline
clinical, laboratory, hemodynamic and LDF data of the patients are presented in table 1,
comparing those with an eGFR less than or equal to those with higher than the median 35
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ml/min/1.73m2. Diabetic (27.6%) and hypertensive nephropathy (18.1%), tubulointerstitial
disease (18.1%) and glomerulonephritis (14.1%) were the most frequent causes of CKD.
Almost all patients took an ACE-inhibitor or angiotensin receptor blocker (88.6%), many of
them a diuretic (74.3%), calcium channel blocker (53.3%) or beta-blocker (54.2%), less
alpha-blocker (18.1%) and centrally effective antihypertensive drugs (13.3%). Sixty-two
percent of the patients were on statins, 22.8% on oral antidiabetics, 21% on insulin, 14.3% on
nitrate and 12.4% on fibrate therapy. Half of the patients took any kind of antiplatelet therapy.
The group with an eGFR below 35 ml/min/1.73 m2 had a worse metabolic status as indicated
by their elevated phosphorus, parathyroid hormone, CRP, urinary albumin-to-creatinine ratio
and lower hemoglobin values. No significant differences were found between these two
groups in respect of their ACh, SNP or PORHHA values. Ang-2, ADMA and SDMA levels,
however, were significantly higher in those with more advanced CKD.
The second table presents Spearman correlation coefficients between different LDF and
serum microvascular biomarkers. There were significant baseline correlations among the three
biochemical parameters and also among the three LDF parameters, but not between the
biochemical and LDF measures. The third table shows independent associations of the six
vascular parameters with other measures at baseline, based on multivariate linear regression
analysis. The highest R2 was found for lnSDMA mainly due to its strong relation to eGFR.
Overall however, the model R2 values for the 6 parameters were small or moderate.
Outcome status was available for all the 105 patients at the end of the follow-up. By that time
a total of 50 primary outcome events occurred in 38 patients. It represents an incidence rate of
CV diseases of 8.5 events per 100 patient-years in our population. Sixteen patients died of CV
causes (acute coronary syndrome n=4, stroke n=3, heart failure n=8, and peripheral artery
disease n=1), and there were 34 additional CV events (acute coronary syndrome n=8, stroke
n=6, heart failure n=13, peripheral artery disease n=7). During follow-up 12 patients died of
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non-CV causes (senile dementia n=5, pneumonia n=2, accidents n=2, lung cancer n=1,
colorectal cancer n=1, pancreatitis n=1).
The fourth table summarizes the results of the uni-and multivariate Cox proportional hazard
regression analyses for all microvascular LDF and biochemical parameters and for those other
baseline variables that showed a significant association with the endpoints. In univariate
models, only lnPORHHA and lnAng-2, but not the other four baseline microvascular
parameters, were significantly related to these two outcomes. In multivariate analyses
lnPORHHA remained an independent predictor of CV mortality and CV events besides age,
CRP and diabetes. While LnAng-2 was a significant predictor of this outcome (CV mortality
and CV events) independent of age, sex, and baseline CV disease, but once diabetes or eGFR
was introduced into the model it lost its statistical significance. When all-cause mortality was
introduced instead of CV mortality as outcome even lnPORHHA lost its predictive value
leaving age, diabetes pulse pressure and the use of fibrates as independent risk factors.
Based on multivariate logistic regressions using the Framingham 10-year CV risk score and
the Framingham score plus lnPORHHA as predictors, both parameters were significantly
related to CV events plus CV mortality (1.07 (1.03-1.11) and 0.66 (0.43-1), respectively). The
Framingham risk score had an overall good discrimination (AUC: 0.75 SE: 0,05) however the
addition of lnPORHHA did not further improve discrimination (AUC: 0.76 SE: 0.05, p=0.54).
In contrast, the NRI showed a significant reclassification improvement of 21.8% (SE 0.09)
using three risk categories (0-19.9, 20-44.9, ≥45%). However, only Framingham score but not 
lnPORHHA was an independent predictor of all-cause mortality plus CV events (1.09 (1.04-
1.14) and 0.75 (0.49-1.14), respectively).
Discussion
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The major finding of our cohort study is that among the tested functional (ACh, SNP,
PORHHA) and biochemical (Ang-2, ADMA, SDMA) microvascular parameters PORHHA
independently predicted CV events and CV mortality in non-dialyzed CKD patients.
Nevertheless the robustness of traditional risk factors seems to outweigh the predictive role of
this microvascular biomarker when all-cause mortality and incidence of CV events are
considered.
The different LDF methods of iontophoresis have frequently been studied in pathological
conditions. Acetylcholine is assumed to cause endothelial-dependent, while sodium
nitroprusside endothelium-independent vasodilation[24]. Later studies however showed, that
the cutaneous blood flow increase induced by acetylcholine administration is also influenced
by axon reflex and prostanoids as well[25], suggesting that the acetylcholine-induced reactive
hyperemia has also endothelium-independent components. When compared to our previous
studies, the magnitude of the evoked hyperemia after acetylcholine and sodium nitroprusside
iontophoresis in this work was between those who had only hypertension and those who were
dialyzed, and lower compared to healthy controls[7]. Surprisingly however, no difference was
found between those with less and more advanced CKD in their acetylcholine or sodium
nitroprusside responses, and eGFR was not an independent determinant of these parameters.
These findings are in agreement with a recent publication, where Thang et al.[26]
demonstrated that in patients with advanced CKD reactive hyperemia for acetylcholine and
sodium nitroprusside iontophoresis were not associated with eGFR.
At baseline both acetylcholine and sodium nitroprusside responses were inversely related to
the presence of diabetes. This is in line with the literature as Beer et al.[27] have previously
shown that diabetes significantly influenced cutaneous vascular response to acetylcholine and
sodium nitroprusside iontophoresis. Moreover, Brooks et al.[28] found a progressive fall of
both acetylcholine and sodium nitroprusside-induced microvascular responsiveness in
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parallel with the development of microvascular complications of diabetes. The use of
antiplatelet medication and diuretics were both independently and negatively associated with
sodium nitroprusside-evoked hyperemia in our study. We suppose that these associations do
not reflect a direct effect, but their use is a sign of the presence of more severe comorbidities,
associated with lower overall microvascular reactivity.
From the different PORH parameters we have chosen hyperemia area (PORHHA), as it reflects
speed, intensity, and duration of the hyperemic response and previously it was associated with
the development of coronary heart disease in ESRD patients [15, 20]. We, however, found no
significant difference in PORHHA between those with less and more advanced CKD, and
eGFR was not an independent determinant of PORHHA. This, together with the results of
iontophoresis, suggests that endothelial dysfunction evaluated by the different LDF tests is an
early process, and that the progression of chronic kidney disease per se does not influence its
severity significantly, until dialysis becomes necessary. On the grander scheme of using
PORH in CKD patients for the assessment and evaluation of cardiovascular risk, we think if
other studies confirm our findings, PORHHA might be a recommended for risk stratification in
all stages of CKD.
PORHHA, however, was inversely and significantly related to brachial pulse pressure which
confirms the known link between micro-and macrovascular function[29]. Stiff central arteries
cause high pulsatility of central aortic pressure, resulting high transmission of pulsatile energy
into the periphery, which is thought to promote microvascular injury [30]. PORHHA was also
inversely associated with the use of calcium channel blockers and fibrates. As both of these
groups of medications were found to be beneficial for vasodilatory responses measured with
flow-mediated vasodilation [31-33], we believe, these associations do not refer to a direct
effect, rather the severity of comorbidities of patients.
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There were significant baseline correlations among the three biochemical parameters of
microvascular dysfunction and also among the three laser Doppler parameters, but not
between the biochemical and laser Doppler measures. This finding suggests first, that the
measured parameters have their internal validity, and second, that the biochemical parameters
provide information on vessel function that is different from what laser Doppler functional
tests provide.
Among the studied LDF parameters only PORHHA, but not ACh or SNP, was found to be a
predictor of CV mortality and CV events. The predictive role of acetylcholine and sodium
nitroprusside iontophoresis for CV events or mortality has not been studied previously[34].
While our current data question the clinical use of iontophoresis for risk prediction in CKD,
more confirmatory follow-up studies are needed in different populations before one may
conclude that iontophoresis should be reserved for the laboratory use.
The predictive role of PORHHA in our patient population is in line with the findings of Kruger
et al, who demonstrated in ESRD patients that development of coronary artery disease was
associated with the postocclusive recruitment of dermal capillaries[15]. While our data are the
first to show an independent predictive value of PORHHA for CV mortality and CV events,
even PORHHA lost its independent predictive role when all-cause mortality and CV events
were considered as outcome. This is perhaps due to the robust effects of classical risk factors,
such as age, diabetes or brachial pulse pressure, and also due to the difference in predictors of
CV and all-cause mortality. The significant NRI means that PORHHA improved prediction of
CV risk over the Framingham scores. It seems therefore that this simple LDF test is worth of
further study and bears the promise of clinical application.
Interestingly, in the final multivariate Cox-proportional regression analysis fibrate use was an
independent predictor of CV events plus all-cause mortality. As only 12.4% of our 105
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patients took fibrates and we had no follow-up data on medication use, this finding requires
cautious and critical interpretation. Although fibrates can increase creatinin, the safety of their
use above GFR 30 ml/min was confirmed by the huge, randomized FIELD study [35].
Regarding to the studied serum markers, previously we found that Ang-2 increases with
advanced CKD[12]. In line with this observation, in our current cohort Ang-2 was also
elevated in more advanced CKD, although in multivariate analysis eGFR failed to remain an
independent determinant of Ang-2. Whether the significant association between phosphorus
and Ang-2 is only the consequence of decreased kidney function, or it represents yet another
facet of mineral bone disease, remains to be investigated. Another independent determinant of
Ang-2 level was CRP, which was also found to be associated with Ang-2 in coronary heart
disease patients[36]. Ang-2, via the loss of Tie-2 signaling, destabilizes the endothelium and
facilitates inflammatory response to cytokines[37], and this may be an explanation for this
association. Finally, Ang-2 was inversely related to serum cholesterol level. The explanation
for this observation is not clear so far, but this finding is in line with our previous study,
where the same inverse relationship was found in more advanced CKD[12].
While in univariate analysis Ang-2 was a predictor of both outcomes, in multivariate analysis
Ang-2 failed to remain an independent risk factor. This is in contrast with our previous study,
where Ang-2 was found to predict mortality in CKD patients independent of other risk
factors[8]. Perhaps the less severe renal failure among our current population may explain for
these contradictory results.
Regarding to ADMA and SDMA, the other two biochemical markers measured in our study,
we found their elevated levels in those with more advanced CKD, which is in line with the
literature data[9, 38]. While ADMA was found to be the predictor of mortality or CV events
in ESRD previously, as well as in patients with advanced CKD[9, 39, 40], in our current study
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neither ADMA nor SDMA predicted the outcomes. We assume that differences in the patient
population or the used medications may have led to this conflicting finding. Almost all of our
patients had hypertension (98%) and most took RAAS (renin-angiotensin-aldosterone system)
inhibitors (88.6%). Previously RAAS inhibitors were found to reduce serum ADMA levels
and that the use of RAAS inhibitors was an independent predictor of arginine/ADMA
ratio[41, 42]. Although no medication was an independent predictor of ADMA in our study,
the use of RAAS inhibitors had the highest point estimate among medications (β:-0.130, 
p=0.138). Moreover, the use of RAAS inhibitors was an independent negative predictor of
SDMA. The ratio of patients who took RAAS inhibitors was much lower in the study of Hov
et al (74%)[40, 41] and Lu et al (34%)[9]. Moreover, our patients were younger compared to
those of Lu et al[9]. Age was an independent predictor of ADMA level in our study and in the
study of Hov et al as well[41]. Furthermore, diabetes was more frequent (47%) among our
patients compared to the study of Hov et al[40, 41]. Interestingly, in the large population-
based study of Böger et al[43], in patients with diabetes ADMA failed to predict mortality.
The same authors hypothesized, that this phenomenon may be explained by the observed
uncoupling of endothelial nitric oxide synthase (eNOS) in diabetes[44]. The activity of
uncoupled eNOS can lead to excessive superoxide production which can have detrimental
effects directly or by reacting with vascular NO to form the highly reactive peroxynitrite. In
this condition the inhibition of the uncoupled eNOS by ADMA or SDMA can have an
unexpected beneficial effect and might modify the survival of patients[44]. This hypothesis
however has never been tested in diabetic CKD patients.
A limitation of our study is the relatively low number of patients involved; however this is
counterbalanced by the long follow-up period and by the use of multiple failure time analysis
both of which likely decreased the chance of a beta-error. Given the relatively low number of
participants and outcome events, we decided to use a stepwise elimination of potential co-
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variates (even those that may be physiologically connected) ), in line with the hypothesis
generating purpose of our study. According to a post-hoc power analysis, given the mean
values and SD observed for lnPORH in participants with and without an outcome (5.83, 6.38,
1.21, respectively), an alpha of 0.05, we had a 69% power to detect the observed difference.
Our sophisticated analysis however probably provided somewhat larger power than the
calculated as it took into account time to the event and also multiple events within
participants. Another limitation comes from the convenience sampling with consecutive
enrollment of patients in the two tertiary care nephrology clinics, and therefore selection bias
that may limit generalizability (i.e. high baseline CV disease risk burden of our patients)
cannot be ruled out.
In conclusions, among the studied LDF and biochemical microvascular parameters only
PORHHA predicted CV events plus CV mortality, although even PORHHA lost its statistical
significance when all-cause mortality plus CV events were considered as outcome. Although
the robustness of traditional, Framingham risk factors seems to outweigh the predictive role of
microvascular biomarkers on all-cause mortality plus CV events, the latter seems to be an
additional marker to improve CV risk assessment in CKD. Our study confirms the role of age,
diabetes or brachial pulse pressure on clinical outcome prediction in CKD patients that may
further be improved by the evaluation of this simple laser-Doppler parameter.
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Table 1. Baseline demographic, clinical, hemodynamic and laboratory characteristics and laser-Doppler test results for all participants and by
eGFR status (over or below the median).
variable all patients >35 ≤35 variable all patients >35 ≤35
n 105 53 52 Cholesterol (mmol/l) 4.88 (1.01) 4.90 (1.10) 4.84 (1.11)
Age (year) 65 (13.1) 64.1 (13.7) 65.9 (12.6) Potassium (mmol/l) 4.59 (0.55) 4.51 (0.51) 4.65 (0.59)
Male % (n) 49 (51) 52 (28) 44 (23) Calcium (mmol/l) 2.36 (0.12) 2.35 (0.10) 2.37 (0.14)
BMI 28.2 (5.0) 27.8 (4.7) 28.7 (5.3) Phosphorus (mmol/l) 1.22 (0.24) 1.14 (0.20) 1.30 (0.24) #
Current smoker % (n) 11 (12) 11 (6) 11 (6) PTH* (pg/ml) 56 (38-102) 45 (25-58) 92 (54-168)#
Baseline CV disease % (n) 62 (65) 55 (29) 69 (36) Albumin (g/l) 45.2 (4.2) 45.0 (4.4) 45.5 (4.1)
Diabetes % (n) 45 (47) 38 (20) 52 (27) CRP* (mg/l) 2.3 (0.9-4.5) 1.60 (0.7-3.1) 3.05 (1.20-6.25)#
Framingham score* 21.4 (13-32.6) 23.1 (12.6-32.7) 20.3 (13.6-32.5) ACR* (mg/mmol) 7.2 (1.7-46) 4.6 (0.98-28.8) 16.7 (3.9-83.1)#
SBP (mmHg) 134 (15.8) 135 (16.2) 134 (15.6) Ang-2*(ng/ml) 3.1 (2.4-4.2) 2.9 (2.2-3.6) 3.4 (3-4.9)#
DBP (mmHg) 73 (9.7) 74 (9.3) 72 (10.1) ADMA* (µmol/l) 0.60 (0.53-0.65) 0.56 (0.52-0.61) 0.62 (0.56-0.68)#
PP (mmHg) 61 (13.4) 61(14.5) 62 (12.4) SDMA* (µmol/l) 0.94 (0.74-1.30) 0.75 (0.61-0.91) 1.27 (1.02-1.95)#
Heart rate (1/min) 66 (12.3) 65 (11.0) 68 (13.5) ACh* (%) 413 (244-614) 436 (276-610) 407 (202-691)
eGFR (ml/min/1.73m2) 40.1 (21.7) 56.1 (18.9) 23.8 (7.12) # SNP* (%) 454 (208-766) 602 (214-791) 372 (179-709)
Hemoglobin (g/l) 126 (14.4) 131 (15.6) 122# (11.7) PORHHA* (PU * sec) 592 (280-1047) 569 (266-1047) 690 (311-1069)
Continuous data are presented as mean (SD) or *median (interquartile range). # p<0.05. Categorical parameters are presented as % (n).
BMI: body mass index; Framingham score: Framingham 10 years cardiovascular risk score; SBP: systolic blood pressure; DBP: diastolic blood
pressure; PP: pulse pressure; eGFR: estimated glomerular filtration rate; PTH: parathormone; CRP: C-reactive protein; ACR: urinary albumin to
creatinine ratio; Ang-2: angiopoietin-2; ADMA: asymmetric dimethylarginin; SDMA: symmetric dimethylarginin. ACh: maximum percent laser
Doppler flow increase in the forearm skin capillaries after acetylcholine iontophoresis; SNP: maximum percent laser Doppler flow increase in the
forearm skin capillaries after sodium nitroprusside iontophoresis; PORHHA: postocclusive reactive hyperemia area; PU: perfusion unit;
Table 2. Spearman correlation coefficients and corresponding p-values between the laser
Doppler and biochemical microvascular parameters.
ACh SNP PORHHA Ang-2 ADMA SDMA
ACh 1 0.498 0.280 -0.161 -0.045 -0.112
0.0 0.001 0.010 0.145 0.683 0.310
SNP 1 0.233 -0.170 -0.153 -0.038
0.0 0.033 0.122 0.164 0.734
PORHHA 1 0.114 0.015 0.112
0.0 0.273 0.883 0.283
Ang-2 1 0.292 0.332
0.0 0.003 0.001
ADMA 1 0.308
0.0 0.002
SDMA 1
0.0
ACh: maximum percent laser Doppler flow increase in the forearm skin capillaries after
acetylcholine iontophoresis; SNP: maximum percent laser Doppler flow increase in the
forearm skin capillaries after sodium nitroprusside iontophoresis; PORHHA: postocclusive
reactive hyperemia area; Ang-2: angiopoietin-2; ADMA: asymmetric dimethylarginin;
SDMA: symmetric dimethylarginin.
Table 3. Variables associated with baseline laser Doppler and biochemical microvascular
parameters.
dependent variable: lnACh model
R2=0.106
explanatory variable estimate SE p partial R2
diabetes -0.598 0.192 0.003 0.106
dependent variable: lnSNP model
R2=0.255
explanatory variable estimate SE p partial R2
diabetes -0.470 0.157 0.004 0.080
antiplatelet -0.435 0.152 0.005 0.069
diuretic -0.404 0.172 0.021 0.049
dependent variable: lnPORHHA model
R2=0.394
explanatory variable estimate SE p partial R2
PP -0.020 0.005 <0.001 0.119
CCB -0.600 0.127 <0.001 0.161
fibrate -0.391 0.180 0.032 0.033
dependent variable: lnAng-2 model
R2=0.415
explanatory variable estimate SE p partial R2
cholesterol -0.171 0.035 <0.001 0.136
phosphorus 0.484 0.180 <0.001 0.112
lnCRP 0.133 0.046 0.004 0.064
heart rate 0.009 0.003 0.007 0.050
age 0.006 0.003 0.041 0.027
lnACR 0.048 0.020 0.047 0.026
dependent variable: lnADMA model
R2=0.168
explanatory variable estimate SE p partial R2
age 0.005 0.001 0.001 0.078
heart rate 0.005 0.001 0.002 0.055
phosphorus 0.157 0.079 0.049 0.034
dependent variable: lnSDMA model
R2=0.760
explanatory variable estimate SE p partial R2
eGFR -0.013 0.001 <0.001 0.395
phosphorus 0.352 0.107 0.001 0.034
BMI -0.012 0.005 0.009 0.020
heart rate 0.005 0.002 0.002 0.023
lnPTH 0.078 0.030 0.012 0.021
lnACR 0.026 0.012 0.032 0.015
RAASinh -0.147 0.072 0.044 0.011
The variables considered in the multivariate linear regression models were age, sex, BMI,
current smoking, diabetes, baseline cardiovascular disease, eGFR, lnCRP, hemoglobin,
cholesterol, phosphorus, lnPTH, albumin, lnACR, systolic blood pressure, brachial pulse
pressure, heart rate, use of ACE-inhibitor or ARB, diuretics, beta-blockers, alpha-blockers,
calcium channel blockers, centrally effective antihypertensive drugs, nitrate, statin, fibrate,
oral antidiabetic drugs, insulin, antiplatelet drugs.
Abbreviations: ln - natural logarithm; BMI: body mass index; eGFR: estimated glomerular
filtration rate; PTH: parathormone; CRP: C-reactive protein; ACR: urinary albumin to
creatinine ratio; ACh: maximum percent laser Doppler flow increase in the forearm skin
capillaries after acetylcholine iontophoresis; SNP: maximum percent laser Doppler flow
increase in the forearm skin capillaries after sodium nitroprusside iontophoresis; PORHHA:
post-occlusive reactive hyperemia area; ADMA: asymmetric dimethylarginin; SDMA:
symmetric dimethylarginin; CCB: calcium-channel blocker; RAASinh: ACE-inhibitors or
ARBs.
Table 4. Uni- and multivariate multiple failure time Cox-proportional hazards regression
analyses of predictors of cardiovascular morbidity and mortality
Outcome:
CV mortality plus CV events
Outcome:
all-cause mortality plus CV events
Univariate model Univariate model
Hazard
Ratio
95% confidence
interval
p Hazard
Ratio
95% confidence
interval
p
lnACh 0.79 0.59 1.05 0.112 0.86 0.64 1.15 0.319
lnSNP 0.93 0.59 1.48 0.789 1.02 0.67 1.56 0.893
lnPORHHA 0.69 0.57 0.84 <0.001 0.75 0.61 0.92 0.005
lnAng-2 1.99 1.25 3.19 0.004 2.02 1.31 3.13 <0.001
lnADMA 1.03 0.23 4.56 0.96 1.59 0.41 6.12 0.49
lnSDMA 1.25 0.64 2.46 0.50 1.51 0.83 2.73 0.17
Age 1.02 1.00 1.04 0.048 1.02 1.00 1.04 0.009
Male gender 0.76 0.43 1.32 0.34 0.84 0.51 1.38 0.50
Current
smoking 0.52 0.17 1.55 0.24 0.67 0.31 1.48 0.33
Diabetes 3.23 1.71 6.08 <0.001 2.58 1.52 4.39 <0.001
CV disease 2.49 1.20 5.13 0.013 2.72 1.42 5.21 0.002
BMI 1.05 0.99 1.11 0.054 1.03 0.98 1.08 0.18
eGFR 0.98 0.96 1.00 0.058 0.98 0.96 0.99 0.015
Hemoglobin 0.99 0.97 1.01 0.50 0.98 0.96 0.99 0.019
Cholesterol 0.85 0.68 1.07 0.18 0.84 0.67 1.04 0.12
Potassium 0.64 0.37 1.11 0.11 0.77 0.47 1.26 0.30
Calcium 1.95 0.13 30.2 0.63 1.65 0.16 17.2 0.68
Phosphorus 0.67 0.21 2.12 0.50 1.10 0.40 3.03 0.84
Albumin 1.03 0.95 1.11 0.38 1.01 0.95 1.07 0.69
lnCRP 1.32 0.98 1.79 0.067 1.38 1.05 1.803 0.018
lnPTH 1.20 0.86 1.68 0.26 1.11 0.81 1.51 0.50
lnACR 1.04 0.90 1.19 0.57 1.03 0.91 1.17 0.55
SBP 1.01 0.99 1.03 0.092 1.01 0.99 1.03 0.056
PP 1.02 1.00 1.05 0.013 1.03 1.01 1.05 <0.001
Heart rate 1.01 0.99 1.03 0.13 1.01 0.99 1.03 0.094
RAASinh 0.64 0.29 1.33 0.22 0.71 0.35 1.42 0.33
Diuretic 1.63 0.73 3.64 0.23 1.56 0.79 3.09 0.20
CCB 1.44 0.82 2.54 0.21 1.33 0.80 2.19 0.27
Beta-blocker 1.14 0.58 2.23 0.70 1.10 0.62 1.96 0.75
Alpha-blocker 1.63 0.93 2.86 0.090 1.48 0.88 2.49 0.14
Centrally eff. 1.38 0.64 2.95 0.41 1.22 0.59 2.51 0.59
Statin 0.89 0.51 1.54 0.67 0.71 0.44 1.16 0.17
Fibrate 2.33 1.10 4.91 0.027 2.62 1.31 5.22 0.006
Nitrate 1.17 0.61 2.23 0.64 0.91 0.49 1.68 0.77
OAD 2.18 1.24 3.85 0.007 1.83 1.08 3.10 0.024
Insulin 2.04 1.08 3.87 0.028 1.68 0.94 3.00 0.08
Antiplatelet 1.20 0.64 2.27 0.57 1.29 0.74 2.25 0.37
Final multivariate model Final multivariate model
Hazard
Ratio
CI 95% p Hazard
Ratio
CI 95% p
ln PORHHA 0.71 0.57 0.89 0.003 - - - -
Age 1.04 1.01 1.06 0.004 1.03 1.00 1.06 0.011
lnCRP 1.26 1.00 1.57 0.045 - - - -
Diabetes 4.81 2.13 10.88 <0.001 2.74 1.56 4.82 <0.001
PP - - - - 1.03 1.01 1.05 0.005
Fibrate - - - - 2.27 1.24 4.17 0.008
Hazard ratios represent a unit increase in the variable.
Abbreviations: CV: cardiovascular; ln: natural logarithm; ACh: maximum percent laser
Doppler flow increase in the forearm skin capillaries after acetylcholine iontophoresis; SNP:
maximum percent laser Doppler flow increase in the forearm skin capillaries after sodium
nitroprusside iontophoresis; PORHAH: post-occlusive reactive hyperemia area; Ang-2:
angiopoietin-2; ADMA: asymmetric dimethylarginin; SDMA: symmetric dimethylarginin;
BMI: body mass index; eGFR: estimated glomerular filtration rate; CRP: C-reactive protein;
PTH: parathormone; ACR: urinary albumin-to-creatinine ratio; SBP: peripheral systolic blood
pressure; PP: pulse pressure; RAASinh: ACE-inhibitors plus ARBs; CCB: calcium channel
blockers; Centrally eff: centrally effective antihypertensive drugs; OAD: oral antidiabetic
drugs; Antiplatelet: antiplatelet drugs.
